首页> 外文期刊>Hepatitis Monthly >PREVALENCE OF SEROLOGIC HEPATITIS B MARKERS IN BLOOD DONORS FROM PUEBLA, MEXICO: THE ASSOCIATION OF RELATIVELY HIGH LEVELS OF ANTI-CORE ANTIBODIES WITH THE DETECTION OF SURFACE ANTIGEN AND GENOMIC DNA
【24h】

PREVALENCE OF SEROLOGIC HEPATITIS B MARKERS IN BLOOD DONORS FROM PUEBLA, MEXICO: THE ASSOCIATION OF RELATIVELY HIGH LEVELS OF ANTI-CORE ANTIBODIES WITH THE DETECTION OF SURFACE ANTIGEN AND GENOMIC DNA

机译:墨西哥PUEBLA血液供体中血清学肝炎B标记的流行:相对较高水平的抗核心抗体与表面抗原和基因组DNA的检测

获取原文
       

摘要

Background: The hepatitis B virus (HBV) causes chronic hepatitis, hepatic cirrhosis, and hepatocellular carcinoma. Surface antigen (HBsAg) detection is a definitive test that can confirm HBV infection, while the presence of antibodies against the core protein (anti- HBc) suggests either a previous or ongoing infection or occult hepatitis B infection (OBI).Objectives: The aim of the present study was to determine the prevalence of anti-HBc and HBsAg in blood donors. Further, the study aimed to estimate the anti-HBc level at which HBV DNA is detected in putative OBI cases, as well as to search for mutations in the “a” determinant associated with the non-detection of HBsAg in serum.Patients and Methods: We conducted a cross-sectional study from 2003–2009. The study included 120, 552 blood donors from the state of Puebla, Mexico. Different commercial systems based on microparticles (enzymatic (MEIA) or chemiluminescent (CMIA)) were used to determine the HBsAg and anti-HBc levels. For the detection of HBV DNA, a nested polymerase chain reaction (nested PCR) was used and the genotypes were determined using Sanger sequencing.Results: Of the 120, 552 blood donors, 1437 (1.19%, 95% CI: 1.12 - 1.26) were reactive to anti-HBc, while 82 (0.066%, 95% CI: 0.053 - 0.079) were reactive to HBsAg. Some 156 plasma samples collected in 2009 from anti-HBc-positive/HBsAg-negative blood donors were submitted for HBVDNA detection in a search for probable OBI. Viral DNA was detected in 27/156 (17.3%, 95% CI: 11.5 - 23.1). Our results show an association between HBV DNA or HBsAg and anti-HBc S/CO levels 3 4.0. All DNA samples were identified as genotype Hand some “a” determinant mutations were identified, although none corresponded to mutations previously reported to hinder the detection of HBsAg by commercial immunoassays.Conclusions: We observed that as the anti-HBc levels increase, there is a higher prevalence of the viral protein HBsAg in blood donors. Samples testing positive for HBV-DNA were seen to exhibit a ten-fold higher presence of anti-HBc S/CO 3 4 than those with S/CO 3 1 and<4.0, which highlights the relevance of anti-HBc determination in blood donor samples.
机译:背景:乙型肝炎病毒(HBV)引起慢性肝炎,肝硬化和肝细胞癌。表面抗原(HBsAg)检测是可以确定HBV感染的确定性测试,而针对核心蛋白的抗体(抗HBc)的存在则表明既往感染或正在进行感染或隐匿性乙型肝炎感染(OBI)。本研究的目的是确定献血者中抗HBc和HBsAg的患病率。此外,该研究旨在评估推定的OBI病例中检测到HBV DNA的抗HBc水平,并寻找与血清中未检测到HBsAg相关的“ a”决定簇的突变。 :我们从2003年至2009年进行了横断面研究。该研究包括来自墨西哥普埃布拉州的120、552个献血者。使用基于微粒的不同商业系统(酶促(MEIA)或化学发光(CMIA))来确定HBsAg和抗HBc水平。为了检测HBV DNA,使用了巢式聚合酶链反应(巢式PCR),并使用Sanger测序确定了基因型。结果:在120 552名献血者中,有1437名献血者(1.19%,95%CI:1.12-1.26)对HBsAg有反应性,而82(0.066%,95%CI:0.053-0.079)对HBsAg有反应性。为了寻找可能的OBI,2009年从抗HBc阳性/ HBsAg阴性献血者收集的约156个血浆样品已提交HBVDNA检测。在27/156中检测到病毒DNA(17.3%,95%CI:11.5-23.1)。我们的结果显示HBV DNA或HBsAg与抗HBc S / CO水平之间存在关联3 4.0。所有DNA样品均被鉴定为基因型Hand。虽然未发现与先前报道的阻碍商业免疫测定法检测HBsAg的突变相对应的突变,但鉴定出一些“ a”决定簇突变。结论:我们观察到,随着抗HBc水平的升高,存在一个献血者中病毒蛋白HBsAg的患病率较高。 HBV-DNA检测呈阳性的样本显示抗-HBc S / CO 3 4的存在比具有S / CO 3 1且<4.0的样本高十倍,这凸显了献血者中抗-HBc测定的相关性样品。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号